SMN1: The Carrier Gene Behind the Leading Genetic Cause of Infant Death

Spinal muscular atrophy (SMA) has a strange distinction in genetics: it's simultaneously one of the most common severe genetic diseases and one of the least talked-about, mostly because carriers are completely healthy. You can carry the exact deletion that causes SMA and never have a single symptom in your life — the disease only appears when a child inherits a non-working copy from both parents.

What SMN1 Does, and What Happens Without It

SMN1 (survival motor neuron 1) produces a protein essential for the health of motor neurons — the nerve cells in your spinal cord that control voluntary muscle movement. When both copies of SMN1 are missing or non-functional, motor neurons progressively degenerate, leading to muscle weakness and wasting that gets worse over time. The severity ranges widely by type, from SMA Type I — onset in the first six months of life, historically fatal by age two without treatment — to milder adult-onset forms.

Humans have a near-identical backup gene called SMN2, which produces a small amount of functional protein on its own. The number of SMN2 copies a person has significantly influences how severe their SMA turns out to be, which is part of why genetic testing (not just symptoms) is central to both diagnosis and treatment planning.

The Math That Makes Carrier Screening Non-Negotiable

Because SMA is autosomal recessive, a child is only affected if both parents happen to be carriers, and even then, there's only a 25% chance per pregnancy that the child inherits both non-working copies. On paper that sounds unlikely. In practice, the math changes fast once you know the carrier frequency is roughly 1 in 40 to 1 in 60 — not 1 in 10,000.

That last row is the point. Roughly 80% of SMA diagnoses occur in families with absolutely no prior history of the disease — both parents were unknowing carriers, and there was no way to predict it without a DNA test. This is precisely why ACMG recommended universal SMN1 carrier screening as far back as 2008, and ACOG followed with its own recommendation shortly after: every person considering pregnancy should be offered SMN1 screening, regardless of family history or ethnicity.

Why Finding Out Before Pregnancy Changes Everything

SMA has gone through one of the most dramatic treatment transformations in modern genetic medicine. A diagnosis that was once almost uniformly fatal in its most severe form now has multiple FDA-approved disease-modifying therapies — including a landmark one-time gene therapy that replaces the function of the missing SMN1 gene directly. But every one of these treatments works best, and in some cases only works meaningfully, when started before symptoms progress — ideally within the first weeks of life, before motor neuron loss becomes irreversible.

The Screening Gap Most People Don't Know About

Standard SMN1 carrier screening looks for the deletion of exon 7, which accounts for the overwhelming majority of SMA cases and is detected with roughly 95% sensitivity. But a small subset of carriers — sometimes called "silent carriers" — have two SMN1 copies on one chromosome and zero on the other, which can appear identical to a non-carrier on standard copy-number tests. Whole genome sequencing data, combined with more detailed dosage analysis, is increasingly used to close this residual gap, which is worth knowing if a partner tests negative but there's still a family history of SMA on either side.